Agent for inhibiting odor of pyrazine derivatives
AssigneeKao Corporation
InventorsAya KATO, Naoko Saito, Michiaki Inoue, Kayoko Nomizu
Life of this patent
Estimating the term…
Abstract
Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.
Claims9
A method of reducing an odor of a pyrazine derivative, wherein the method comprises coexisting an odor of a pyrazine derivative with at least one compound selected from the group consisting of the following compounds:
- 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol;
- 5-methyl-2-(1-methylethyl)-phenol;
- 3,7-dimethyl-2,6-octadienal;
- phenylethyl salicylate;
- 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthalenyl)-ethanone;
- isolongifolanone;
- 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (α-ionone);
- 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (β-ionone);
- vetiverol;
- 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7-tetramethyl-naphthalene;
- α-amylcinnamic aldehyde;
- α-methyl-4-(1-methylethyl)-benzenepropanal;
- 4-methyl-3-decen-5-ol;
- 1-(2-tert-butylcyclohexyloxy)-2-butanol;
- 2-methoxy-1-(phenylmethoxy)-4-(1-propenyl)-benzene;
- α-methyl-β-(p-tert-butylphenyl)-propionaldehyde;
- l(−)-menthol;
- ω-6-hexadecenelactone;
- 2-(2-(4-methyl)-3-cyclohexen-1-yl)-propylcyclopentanone;
- formaldehyde cyclododecyl ethyl acetal;
- 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1H-3a,7-methanoazulen-5-yl)-ethanone;
- β-methyl naphthyl ketone;
- cedryl acetate;
- (5E)-3-methylcyclopenta-5-decen-1-one;
- cinnamaldehyde;
- 4-(1-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone;
- α-hexylcinnamic aldehyde;
- 2-phenylpropionaldehyde;
- 3,7-dimethyl-6-octenal;
- dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan;
- 4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1-cyclopentan-3-one;
- α-isomethyl ionone;
- 3,7-dimethyl-1-octanol;
- cedryl methyl ether;
- muscone;
- 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol;
- 2-cyclohexylpropanal;
- γ-undecalactone;
- cyclopentadecanolide;
- 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten-1-one;
- 2,4-dimethyl-3-cyclohexene-1-carboxyaldehyde;
- 2,4,6-trimethyl-3-cyclohexene-1-carboxyaldehyde;
- 3,5,6-trimethyl-3-cyclohexene-1-carboxyaldehyde;
- 6,10-dimethyl-3-oxa-9-undecenal;
- dimethyl benzyl carbinyl acetate;
- ethyl-(3aα,4α,7α,3aα)-octahydro-4,7-methano-3aH-indene-3a-carboxylate;
- 2-pentyl-3-methyl-2-cyclopenten-1-one;
- phenylhexanol;
- 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one;
- 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone;
- cis-4-isopropylcyclohexylmethanol;
- 1-allyl-3-methoxy-4-hydroxybenzene;
- (E)-3,7-dimethyl-2,6-octadien-1-ol;
- 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone;
- 1,4-dioxacycloheptadecane-5,17-dione;
- hexyl salicylate;
- and
- α-methyl-3,4-methylenedioxyhydrocinnamic aldehyde.
A method of antagonizing responses of an olfactory receptor OR5K1, wherein the method includes applying, to an olfactory receptor OR5K1, at least one compound selected from the group consisting of the following compounds:
- 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol;
- 5-methyl-2-(1-methylethyl)-phenol;
- 3,7-dimethyl-2,6-octadienal;
- phenylethyl salicylate;
- 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthalenyl)-ethanone;
- isolongifolanone;
- 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (α-ionone);
- 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (β-ionone);
- vetiverol;
- 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7-tetramethyl-naphthalene;
- α-amylcinnamic aldehyde;
- α-methyl-4-(1-methylethyl)-benzenepropanal;
- 4-methyl-3-decen-5-ol;
- 1-(2-tert-butylcyclohexyloxy)-2-butanol;
- 2-methoxy-1-(phenylmethoxy)-4-(1-propenyl)-benzene;
- α-methyl-β-(p-tert-butylphenyl)-propionaldehyde;
- l(−)-menthol;
- ω-6-hexadecenelactone;
- 2-(2-(4-methyl)-3-cyclohexen-1-yl)-propylcyclopentanone;
- formaldehyde cyclododecyl ethyl acetal;
- 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1H-3a,7-methanoazulen-5-yl)-ethanone;
- β-methyl naphthyl ketone;
- cedryl acetate;
- (5E)-3-methylcyclopenta-5-decen-1-one;
- cinnamaldehyde;
- 4-(1-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone;
- α-hexylcinnamic aldehyde;
- 2-phenylpropionaldehyde;
- 3,7-dimethyl-6-octenal;
- dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan;
- 4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1-cyclopentan-3-one;
- α-isomethyl ionone;
- 3,7-dimethyl-1-octanol;
- cedryl methyl ether;
- muscone;
- 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol;
- 2-cyclohexylpropanal;
- γ-undecalactone;
- cyclopentadecanolide;
- 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten-1-one;
- 2,4-dimethyl-3-cyclohexene-1-carboxyaldehyde;
- 2,4,6-trimethyl-3-cyclohexene-1-carboxyaldehyde;
- 3,5,6-trimethyl-3-cyclohexene-1-carboxyaldehyde;
- 6,10-dimethyl-3-oxa-9-undecenal;
- dimethyl benzyl carbinyl acetate;
- ethyl-(3aα,4α,7α,3aα)-octahydro-4,7-methano-3aH-indene-3a-carboxylate;
- 2-pentyl-3-methyl-2-cyclopenten-1-one;
- phenylhexanol;
- 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one;
- 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone;
- cis-4-isopropylcyclohexylmethanol;
- 1-allyl-3-methoxy-4-hydroxybenzene;
- (E)-3,7-dimethyl-2,6-octadien-1-ol;
- 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone;
- 1,4-dioxacycloheptadecane-5,17-dione;
- hexyl salicylate;
- and
- α-methyl-3,4-methylenedioxyhydrocinnamic aldehyde.
Dependencies are inferred from the claim text.